RCC cells transfected with DDX11 siRNA or control siRNA were treated with a clinically approved PARP inhibitor, olaparib; subsequently, cell proliferation was evaluated to investigate the association between DDX11 expression and the sensitivity to PARP inhibition. This evidence concerns the gene DDX11 and renal cell carcinoma.